Added to YB: 2025-09-19
Pitch date: 2025-06-30
RARE [neutral]
Ultragenyx Pharmaceutical Inc.
-0.17%
current return
Author Info
No bio for this author
Company Info
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Market Cap
$2.8B
Pitch Price
$36.29
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.05
P/E
-5.34
EV/Sales
5.22
Sector
Biotechnology
Category
growth
Sands Capital Select Growth Strategy Portfolio Holding: Ultragenyx Pharmaceutical Inc.
RARE (holding update): Leading rare disease developer with strong execution track record and expanding commercial franchise. Shares flat Q2 awaiting Phase 3 osteogenesis imperfecta interim analysis. Underrecognized pipeline + growing commercial ops = compelling long-term opportunity.
Read full article (1 min)